Background

Memantine is an N-methyl-D-aspartate receptor (NMDA-R) antagonist, approved for dementia, but also studied in pediatric autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

Methods

We reviewed children treated with memantine in a single-centre pediatric neurology clinic. Clinical data extracted included age, sex, weight, clinical history, reason for memantine prescription, period of treatment trial and dosage, treatment response, side effects, and concomitant medications.

Results

Eight patients met inclusion criteria with diagnoses including developmental and epileptic encephalopathy, focal epilepsy, ASD, ADHD. Four reported clear cognitive improvement, though two of these started other concurrent treatments at the time of memantine initiation. One of three patients with poorly-controlled epilepsy, a girl with a GRIN2A variant of uncertain significance, had a clear reduction in seizure frequency. No serious adverse events were noted.

Conclusions

Memantine is generally well-tolerated in children, and may have potential benefit for a broad range of pediatric neurodevelopmental disorders.

中文翻译：

---

美金刚在儿科神经科诊所使用的回顾性分析

背景

Memantine 是一种 N-甲基-D-天冬氨酸受体 (NMDA-R) 拮抗剂，被批准用于痴呆症，但也在儿童自闭症谱系障碍 (ASD) 和注意力缺陷多动障碍 (ADHD) 中进行了研究。

方法

我们回顾了在单中心儿科神经病学诊所接受美金刚治疗的儿童。提取的临床数据包括年龄、性别、体重、临床病史、美金刚处方原因、治疗试验期和剂量、治疗反应、副作用和伴随药物。

结果

8 名患者符合纳入标准，诊断包括发育性和癫痫性脑病、局灶性癫痫、ASD、ADHD。四个报告了明显的认知改善，尽管其中两个在美金刚开始时开始了其他并行治疗。三名控制不佳的癫痫患者中的一名，一名具有不确定意义的GRIN2A变异的女孩，癫痫发作频率明显降低。没有注意到严重的不良事件。

结论

美金刚在儿童中通常具有良好的耐受性，并且可能对广泛的儿科神经发育障碍具有潜在益处。